Yusuke Miyazaki

16PUBLICATIONS

29CO-AUTHORS

Molecular targetsRheumatology and arthritisPredictive and prognostic markersMedical infection agents (incl. prions)Autoimmunity

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (16)

Sort by Publication Date:

|May 18, 2026

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

|May 12, 2026

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

|Mar 09, 2026

Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study.

Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada

|Jan 16, 2026

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Masanobu Ueno, Koshiro Sonomoto, Hiroaki Tanaka

|Jun 19, 2025

Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial.

Yusuke Miyazaki, Nobuko Horiuchi, Shunsuke Okamoto

|Feb 26, 2025

Association of peripheral CD8<sup>+</sup> T cell activation with disease activity and treatment resistance in systemic lupus erythematosus.

Yuya Fujita, Shingo Nakayamada, Satoshi Kubo

Pageof 3

Frequent Collaborators

16 joint publications

Yoshiya Tanaka

14 joint publications

Satoshi Kubo

Masanobu Ueno

Koshiro Sonomoto

Yuya Fujita

Shingo Nakayamada

Ryuichiro Kanda